Clinical Trials Browser

Phase 1/2 × Cholangiocarcinoma × bemarituzumab × Clear all

NCT05325866 2026-02-04

FORTITUDE-301

BreastGastrointestinalGynecologicHead & NeckThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Uterine Cervical Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms